They may have to turn to scumbags’
MARCUS Davies believes last week s court decision will only act to push MS sufferers into the murky world of drug dealers. Instead of giving a donation of £5 for pain-relieving chocolate bars, Mr Davies told The Hunts Post that MS sufferers would have to
MARCUS Davies believes last week's court decision will only act to push MS sufferers into the murky world of drug dealers.
Instead of giving a donation of £5 for pain-relieving chocolate bars, Mr Davies told The Hunts Post that MS sufferers would have to "pay £25 to drug-dealing scumbags"
He said: "I'm ever so proud to have helped so many people, but these people are now in great jeopardy."
Mr Davies said the business, THC4MS (Therapeutic Help from Cannabis for Multiple Sclerosis) never paid for the cannabis it supplied. It was given to them by UK growers.
You may also want to watch:
"We never actually bought cannabis from the illegal market. (Our suppliers) are good, honest people who know that this is the best medicine in the world."
He added: "In our mission statement, it says the supply of cannabis chocolate bars will continue until there was a viable alternative.
- 1 Homes plan will 'breathe new life' into town
- 2 Dramatic drop in face-to-face GP appointments
- 3 Shops, homes and office space plan for town centre building
- 4 Read our focus on Ramsey town centre
- 5 Cambridgeshire police officer dismissed after conduct hearing
- 6 Bullying and insider trader claims pile up against former deputy leader
- 7 Grants handed out to help people with cancer in Hunts total £17,000
- 8 'Am I being overcharged for gas and electricity'?
- 9 WATCH: One minute silence to honour the Duke
- 10 New Shoe Zone 'concept store' opens
"That has happened, there is now Sative, a natural product with plant extracts that costs £100 a bottle."
Mr Davies said the bottle contains 52 doses but only lasts two weeks once opened. This means a cost of £200 a month - a price the NHS cannot afford.
He said treatment had been trialled in Europe where the manufacturers, GW Pharmaceuticals, were hoping to get a licence.
Mr Davies, who said he is a shareholder in the company, added: "It was cleared for use in the UK in November 2005 but primary care trusts decided that the drug was too expensive.